Spots Global Cancer Trial Database for Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
Official Title: A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations
Study ID: NCT05258279
Study Description
Brief Summary: The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Juntendo Urayasu Hospital, Urayasu, Chiba, Japan
St. Marianna University Hospital, Kawasaki, Kanagawa, Japan
Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
Saitama Cancer Center, Ina, Saitama, Japan
Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
Chiba University Hospital, Chiba, , Japan
Contact Details
Name: Ryo Ko, MD, PhD
Affiliation: Department of Respiratory Medicine, Juntendo University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
